Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family of devices, iDose TR (sustained-release glaucoma therapy), and Epioxa (incision-free therapy for keratoconus, FDA approved in 2025). The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $185,610 | $336,181 |
| Gross Profit | $151,594 | $268,826 |
| Gross Margin | 82% | 80% |
| Operating Expenses | $168,861 | $305,949 |
| Loss from Operations | $(17,267) | $(37,123) |
| Net Loss | $(18,377) | $(38,160) |
| Net Loss Per Share (Basic & Diluted) | $(0.31) | $(0.65) |
Liquidity and Balance Sheet Highlights (as of June 30, 2026)
- Cash and Cash Equivalents: $114.5 million
- Short-term Investments: $171.7 million
- Total Current Assets: $515.8 million
- Total Current Liabilities: $102.3 million
- Working Capital: $413.4 million
- Accumulated Deficit: $(971.3) million
- Debt: No traditional long-term debt; liabilities include finance lease obligations of $67.3 million and operating lease liabilities of $35.5 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 50% year-over-year (Q2 2026 vs. Q2 2025) and 46% for the six-month period. Growth was driven primarily by higher volumes of iDose TR (which has a higher net sales price) and the commercial launch of Epioxa.
- Geographic Performance: U.S. Glaucoma sales rose 64% in Q2; International Glaucoma sales rose 17%, aided by favorable foreign exchange rates (Euro, Australian Dollar, Brazilian Real) but partially offset by reimbursement challenges in Germany.
- Corneal Health: Sales increased 48% in Q2, driven by the transition from Photrexa to Epioxa in the U.S. market.
- Expense Increases: Operating expenses rose 41% in Q2 and 37% for the six months. SG&A increased due to higher compensation (including $9.4M in stock-based compensation in Q2) and commercial infrastructure expansion. R&D increased 40% due to core research and clinical expenses.
- Profitability: While the net loss narrowed slightly in Q2 ($18.4M vs. $19.7M prior year), the company remains unprofitable with a significant accumulated deficit.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Reimbursement: CMS assigned a permanent HCPCS J-code (J2789) for Epioxa, effective July 1, 2026. Five of seven Medicare Administrative Contractors (MACs) issued proposed Local Coverage Determinations (LCDs) for iDose TR in Q2; finalization is pending.
- Product Transition: The company is transitioning commercial efforts and manufacturing from Photrexa to Epioxa, with completion projected by Q3 2026. This may cause temporary disruption in the U.S. Corneal Health franchise.
- Capital Expenditures: The company plans to begin construction in 2026 on a new 200,000 sq. ft. R&D and manufacturing facility in Huntsville, Alabama, with anticipated capital expenditures exceeding $80.0 million over the project's life.
- Liquidity: Management believes existing cash, investments, and operating cash flows are sufficient to meet obligations for at least the next 12 months.
Key Risks and Contingencies
- Legal Proceedings: Glaukos is engaged in litigation against SpyGlass Pharma, Inc. and former employee Long Doan regarding alleged theft of trade secrets. The trial is set for January 26, 2027. The court previously denied motions to dismiss Glaukos's claims.
- Regulatory & Reimbursement: Risks include potential changes in Medicare payment rates, MAC coverage determinations, and the impact of the "One Big Beautiful Bill Act" (OBBBA) on tax provisions.
- Operational Risks: Reliance on single manufacturing sites (San Clemente, CA; Burlington, MA) and limited third-party suppliers creates vulnerability to disruptions. Cybersecurity and AI implementation risks are also highlighted.
- Profitability: The company has incurred significant losses since inception and may not reach sustained profitability.
Investor Verification Checklist
- Reimbursement Status: Verify the finalization of MAC LCDs for iDose TR and the adoption of the new Epioxa J-code by commercial payers.
- Product Transition: Monitor the sales impact of the transition from Photrexa to Epioxa in Q3 and Q4 2026.
- Legal Outcomes: Track the progress of the SpyGlass/Doan trade secret litigation and potential counterclaims.
- Cash Burn vs. Revenue: Assess whether the 50% revenue growth is sufficient to offset the 40%+ increase in operating expenses to narrow the net loss trajectory.
- Capital Allocation: Review the timeline and funding requirements for the new Huntsville, Alabama facility construction.